EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS). The HIFU division develops, manufactures, and markets devices for the minimally invasive destruction of various types of localized tumors using HIFU technology. It offers Ablatherm, a HIFU device for the treatment of organ-confined prostate cancer, referred to as T1-T2 stage; and Focal One device, a HIFU robotic device for the focal therapy of localized prostate cancer. This division also leases equipment; sells consumables; and offers treatment related services and maintenance services. The UDS division develops, manufactures, markets, and services medical devices for the minimally invasive diagnosis or treatment of urological disorders, primarily urinary stones and other clinical indications. It offers lithotripters, such as Sonolith i-move and Sonolith i-sys for the treatment of urinary tract stones by means of extracorporeal shockwave lithotripsy technology. This division also leases lithotripters; sells disposables and spare parts; and provides maintenance services. The company markets and sells its products through its direct marketing and sales organization, as well as through third-party distributors and agents. Its customers include public and private hospitals, urology clinics, and research institutions. The company was founded in 1979 and is headquartered in Vaulx-en-Velin, France.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EDAP
Previous Symbol
CUSIPN/A
Phone33-04-72-15-31-50
Debt
Debt-to-Equity Ratio0.07
Current Ratio2.41
Quick Ratio1.97
Price-To-Earnings
Trailing P/E Ratio-222.00
Forward P/E Ratio-44.40
P/E GrowthN/A
Sales & Book Value
Annual Sales$40.74 million
Price / Sales1.58
Cash Flow$0.0424 per share
Price / Cash Flow52.32
Book Value$0.98 per share
Price / Book2.27
Profitability
EPS (Most Recent Fiscal Year)($0.01)
Net Income$-760,000.00
Net Margins-3.93%
Return on Equity-4.08%
Return on Assets-2.17%
Miscellaneous
Employees200
Outstanding Shares29,000,000
Market Cap$69.01 million
OptionableOptionable
Edap Tms (NASDAQ:EDAP) Frequently Asked Questions
What is Edap Tms' stock symbol?
Edap Tms trades on the NASDAQ under the ticker symbol "EDAP."
How were Edap Tms' earnings last quarter?
Edap Tms SA (NASDAQ:EDAP) released its quarterly earnings data on Wednesday, November, 14th. The medical equipment provider reported ($0.02) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.02). The medical equipment provider earned $9.47 million during the quarter, compared to analyst estimates of $10.34 million. Edap Tms had a negative net margin of 3.93% and a negative return on equity of 4.08%. View Edap Tms' Earnings History.
When is Edap Tms' next earnings date?
What price target have analysts set for EDAP?
1 Wall Street analysts have issued 1 year price targets for Edap Tms' shares. Their predictions range from $7.00 to $7.00. On average, they expect Edap Tms' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 215.3% from the stock's current price. View Analyst Price Targets for Edap Tms.
What is the consensus analysts' recommendation for Edap Tms?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edap Tms in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Edap Tms.
What are Wall Street analysts saying about Edap Tms stock?
Here are some recent quotes from research analysts about Edap Tms stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $6 price target. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based solely on the HS-110 opportunity in NSCLC, and only on the U.S. market based on what we consider to be modest penetration rates." (11/16/2018)
- 2. According to Zacks Investment Research, "EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. " (11/6/2018)
Has Edap Tms been receiving favorable news coverage?
Press coverage about EDAP stock has been trending very negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Edap Tms earned a daily sentiment score of -3.8 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Who are some of Edap Tms' key competitors?
Some companies that are related to Edap Tms include Cutera (CUTR), BioLife Solutions (BLFS), Semler Scientific (SMLR), Rockwell Medical (RMTI), Fonar (FONR), Electrocore (ECOR), Zynex (ZYXI), Stereotaxis (STXS), Second Sight Medical Products (EYES), IRIDEX (IRIX), Viveve Medical (VIVE), Soleno Therapeutics (SLNO), Precision Optics (PEYE), Digirad (DRAD) and ENDRA Life Sciences (NDRA).
Who are Edap Tms' key executives?
Edap Tms' management team includes the folowing people:
- Mr. Marc Oczachowski, CEO & Exec. Director (Age 48)
- Mr. Franois Dietsch, Chief Financial Officer (Age 42)
- Ms. Blandine Confort, Investor Relations Officer and Sec.
- Ms. Judith Johannsen, Sales Director for Germany Austria & Switzerland and Gen. Mang. of Edap Gmbh
- Mr. Noah J. Bartsch, VP of Global Medical, Regulatory and Quality Affairs
Who are Edap Tms' major shareholders?
Edap Tms' stock is owned by a number of of retail and institutional investors. Top institutional investors include Fosun International Ltd (0.59%).
Which major investors are buying Edap Tms stock?
EDAP stock was acquired by a variety of institutional investors in the last quarter, including Fosun International Ltd.
How do I buy shares of Edap Tms?
Shares of EDAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Edap Tms' stock price today?
One share of EDAP stock can currently be purchased for approximately $2.22.
How big of a company is Edap Tms?
Edap Tms has a market capitalization of $69.01 million and generates $40.74 million in revenue each year. The medical equipment provider earns $-760,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Edap Tms employs 200 workers across the globe.
What is Edap Tms' official website?
How can I contact Edap Tms?
Edap Tms' mailing address is Parc d'Activites la Poudrette-Lamartine 4/6 rue du Dauphine, Vaulx-en-Velin I0, 69120. The medical equipment provider can be reached via phone at 33-04-72-15-31-50 or via email at [email protected]
MarketBeat Community Rating for Edap Tms (NASDAQ EDAP)
MarketBeat's community ratings are surveys of what our community members think about Edap Tms and other stocks. Vote "Outperform" if you believe EDAP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDAP will underperform the S&P 500 over the long term. You may vote once every thirty days.
